Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy

Asia-Pacific Journal of Clinical Oncology

Volumn 3, Issue 2, 2007, Pages 79-83

  Gilani, Mitra Modares ^a   Hasanzadeh, Malihe ^b   Ghaemmaghami, Fatemeh ^a   Ramazanzadeh, Fatemeh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapy; Diphereline; GnRH analog; Premature ovarian failure

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DIPHERELINE; ETOPOSIDE; GONADORELIN DERIVATIVE; GONADOTROPIN; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE FERTILITY; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; OVARY CANCER; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE HEALTH; SIDE EFFECT; WOMEN'S HEALTH;

EID: 34250007414     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2007.00089.x     Document Type: Article

References (24)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1991; 41: 19-36.
2. Birch JM, Marsden HB, Jones PH, Pearson D, Blair V. Improvement in survival from childhood cancer: Results of a population based survey over 30 years. Br Med J (Clin Res Ed) 1988; 296: 1372-6.
3. Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997; 29: 199-206.
4. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone releasing hormone agonist inhibits cyclophosphamide - induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365-72.
5. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: 1620-6.
6. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig 2001; 8: 60-4.
7. Pereyra Pacheco B, Mendez Ribas JM, Milone G et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report. Gynecol Oncol 2001; 81: 391-7.
8. Krause W, Pfluger KH. Treatment with the gonadotropin releasing hormone agonist buserelin to protect spermatogenesis agonist cytotoxic treatment in young men. Andrologia 1989; 21: 265-70.
9. Waxman JH, Ahmed R, Smith D et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987; 19: 159-62.
10. Silber TJ. Ethical Issues in the Treatment of Children and Adolescents. C. B. Slack, Thorofare, NJ 1983.
11. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006; 11: 422-34.
12. Cusido L, Pujol R, Egozcue J, Garcia M. Cyclophosphamide-induced synaptonemal complex damage during meiotic prophase of female Rattus norvegicus. Mutat Res 1995; 325: 131-41.
13. Samaan NA, de Asis D, Buzdar A, Blumenschein G. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 1978; 41: 2084-7.
14. Barlow D. Premature ovarian failure. Baillieres Clin Obstet Gynecol 1996; 10: 361-85.
15. Shiromizu K, Thorgeirsson SS, Mattison DR. Effect of cyclophosphamide on oocyte and follicle number in Sprague-Dawley rats, C57BL/6N and DBA/2N mice. Pediatr Pharmacol 1984; 4: 213-21.
16. Giri N, Vowels M, Barr A, Mameghan H. Successful pregnancy after total body irradiation and bone marrow transplantation for acute leukemia. Bone Marrow Transplant 1992; 10: 93-5.
17. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981; 58: 849-51.
18. Andrew CV, Verbitsky M, Stein P, Chemes H, Tesone M. Efecto del tratamiento con un analogo de la hormona liberadora de gonadotrofinas (GnRH) acetato de luproide (LA) a ratas prepuberes superovuladas. Medicina (B Aires) 1995; 65: 583-7.
19. Guerrero HE, Stein P, Asch RH, Polak E, Tesone M. Effect of a gonadotropin-releasing hormone agonist on luteinizing hormone receptors and steroidogenesis in ovarian cells. Fertil Steril 1993; 59: 803-9.
20. Friedman AJ, Barbieri RL. Current problems in obstetrics, gynecology and fertility. In: Friedman AJ (ed.). Leuprolide Acetate: Applications in Gynecology, Vol. 1. Yearbook Medical Publishers, Chicago, IL 1989; 30-67.
21. Frase HM, Bramley TA, Miller WR, Sharpe RH. Extra pituitary actions of LH Rh analogues in tissues of the human female and investigation of the existence and function of LH Rh like peptides. Prog Clin Biol Res 1986; 22: 29-33.
22. Conn PM, Staley D, Jinnah H et al. Molecular mechanism of gonadotropin-releasing hormone action. J Steroid Biochem 1985; 23: 703-10.
23. Minaretzis D, Jakubonoski M, Mostola JF, Pavlou SN. Gonadotropin- releasing hormone receptor gene expression in human ovary and granulose lutein cells. Clin Endocrinol Metab 1995; 80: 430-4.
24. Billig H, Furuta I, Hsueh AJ. Estrogens inhibit and androgens enhance ovarian granulose cell apoptosis. Endocrinology 1993; 133: 2204-12.